Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome

Medical Hypotheses

Volumn 65, Issue 1, 2005, Pages 152-154

  Yamagishi, S ^a   Nakamura, K ^a   Takeuchi, M ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; CARBOHYDRATE; GLUCOSE;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; ENZYME INHIBITORS; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; POSTPRANDIAL PERIOD;

EID: 18944403493     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.12.008     Document Type: Article

References (12)

1. A.J. Scheen Management of the metabolic syndrome Minerva Endocrinol 29 2004 31 45
2. W.A. Hsueh, and M.J. Quinones Role of endothelial dysfunction in insulin resistance Am J Cardiol 92 2003 10J 17J
3. R.J. Heine, and J.M. Dekker Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease Diabetologia 45 2002 461 475
4. P. Rosen, P.P. Nawroth, G. King, W. Moller, H.J. Tritschler, and L. Packer The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society Diabetes Metab Res Rev 17 2001 189 212
5. A. Ceriello Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications Diabetes Nutr Metab 12 1999 42 46
6. R.S. Ronson, M. Nakamura, and J. Vinten-Johansen The cardiovascular effects and implications of peroxynitrite Cardiovasc Res 44 1999 47 59
7. E.M. Kurowska Nitric oxide therapies in vascular diseases Curr Pharm Des 8 2002 155 166
8. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM trial research group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM trial research group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003;290:486-94
10. M. Hanefeld, J.L. Chiasson, C. Koehler, E. Henkel, F. Schaper, and T. Temelkova-Kurktschiev Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance Stroke 35 2004 1073 1078
11. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16
12. H.W.M. Breuer Review of acarbose therapeutic strategies in the long-term treatment and in the prevention of type 2 diabetes Int J Clin Pharm Ther 41 2003 421 440